Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Immix Biopharma (NASDAQ:IMMX) will participate in the Jefferies Global Healthcare Conference June 2-4, 2026 in New York.
The company said it will host one-on-one institutional investor meetings and that a replay link will be posted to its Presentation & Events page on the investor website when available.
Positive
- None.
Negative
- None.
News Market Reaction – IMMX
In the Apr 9 session, IMMX gained 11.43%, reflecting a significant positive market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 36 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Trial enrollment complete | Positive | +5.3% | Completed enrollment in BLA-enabling NEXICART-2 trial with Q3 2026 topline guided. |
| Mar 03 | Investor conferences | Neutral | -2.5% | Announced participation in two March 2026 institutional investor conferences in Miami Beach. |
| Jan 28 | Breakthrough designation | Positive | +3.4% | FDA Breakthrough Therapy Designation for NXC-201 based on NEXICART-2 Phase 2 interim data. |
| Dec 09 | Offering closing | Negative | +2.0% | Closed upsized $100M underwritten offering of common stock and pre-funded warrants. |
| Dec 07 | Offering pricing | Negative | +10.6% | Priced upsized $100M underwritten equity and pre-funded warrant offering for NXC-201 funding. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with clear clinical or regulatory significance (Breakthrough designation, BLA-enabling trial milestones) tended to see positive price alignment, while financings showed positive price reactions despite their typically dilutive nature.
Over the last six months, IMMX reported several key milestones. On Dec 7–9, 2025, it priced and closed an upsized $100 million equity and pre-funded warrant offering, which still saw positive next-day moves. In Jan 2026, the company received FDA Breakthrough Therapy Designation for NXC‑201, with shares rising 3.37%. Completion of enrollment in the BLA‑enabling NEXICART‑2 trial on Mar 30, 2026 also coincided with a 5.28% gain, underscoring market focus on regulatory and clinical progress alongside capital-raising activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
